EFFECT OF IBUDILAST - A NOVEL ANTIASTHMATIC AGENT, ON AIRWAY HYPERSENSITIVITY IN BRONCHIAL-ASTHMA

被引：51

作者：

KAWASAKI, A

HOSHINO, K

OSAKI, R

MIZUSHIMA, Y

YANO, S

机构：

[1] First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Toyama 930-01

来源：

JOURNAL OF ASTHMA | 1992年 / 29卷 / 04期

关键词：

D O I：

10.3109/02770909209048938

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Ibudilast, a unique agent with vasodilating and antiallergic actions, was studied in 1 3 asthmatics for its effect on airway hypersensitivity to histamine inhalation. The PC20 values improved significantly from 355.6 to 620.5-mu-g/ml at 3 months and further to 731.4-mu-g/ml at 6 months following the initial treatment with ibudilast (20 mg twice daily orally). In addition, the severity of the attacks decreased significantly. Improvements in the PC20 and asthmatic symptoms also were observed in the disodium chromoglycate group, but these were equal to or lesser than those in the ibudilast group. No improvement was observed in the untreated control group. These results suggest that ibudilast would be an effective agent for improving nonspecific airway hypersensitivity in asthmatics.

引用

页码：245 / 252

页数：8

共 15 条

[1]

Cox J.S.G., Disodium cromoglycate (FPL 670) ('Intal'): a specific inhibitor of reaginic antibody‐antigen mechanisms, Nature, 216, pp. 1328-1329, (1967)

[2]

Koda A., Nagai H., Watanabe S., Yanagihara Y., Sakamoto K., Inhibition of hypersensitivity reactions by a new drug, N(3′,4′‐dimethoxycinnamoyl) anthranilic acid (N—5′), J Allergy Clin Immunol, 57, pp. 396-407, (1976)

[3]

Martin U., Roemer D., The pharmacological properties of a new orally active anti‐anaphylactic compound: ketotifen, a benzocydoheptathiophene, Arzneim‐Forsch, 28, pp. 770-782, (1978)

[4]

Tasaka K., Akagi M., Anti‐allergic properties of a new histamine antagonist, 4‐(p‐chlorobenzyl)‐2‐[N‐methyl‐perhydroazepinyl‐(4)]‐1,(2H)‐phthalazinone hydrochloride (azelastine), Arzneim‐Forsch, 29, pp. 488-493, (1979)

[5]

Saijo T., Kuriki H., Ashida Y., Makino H., Maki Y., Mechanism of the action of amoxanox (AA‐673), an orally active antiallergic agent, Int Arch Allergy Appl Immun, 78, pp. 43-50, (1985)

[6]

Morinaka Y., Takahashi K., Hata S., Antiallergic agents. I. Pyranoquinoline derivatives, Eur J Med Chem, 16, pp. 251-256, (1981)

[7]

Ohashi M., Kito J., Nishino K., Mode of cerebral vasodilating action of KC‐404 in isolated canine basilar artery, Arch Int Pharmacodyn, 280, pp. 216-229, (1986)

[8]

Nishino K., Ohkubo H., Ohashi M., Kara S., Kito J., Irikura T., KC‐404: A potential anti‐allergic agent with antagonistic action against slow reacting substance of anaphylaxis, Japan J Pharmacol, 33, pp. 267-278, (1983)

[9]

Tsaka K., Anti‐allergic drugs, Drugs Today, 22, pp. 101-133, (1986)

[10]

Ohashi M., Ohkubo H., Kito J., Nishino K., A new vasodilator 3‐isobutyryl‐2‐isopropylpyrazolo[1,5‐a] pyridine (KC‐404) has a dual mechanism of action on platelet aggregation, Arch Int Pharmacodyn, 283, pp. 321-334, (1986)

← 1 2 →